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T cells are pivotal in the immune defense against cancers and infectious agents. To mount
an effector response against cancer cells, T cells need to migrate to the cancer-site,
engage in contacts with cancer cells, and perform their effector functions. Adoptive T
cell therapy is an effective strategy as treatment of complications such as relapse or
opportunistic infections after hematopoietic stem cell transplantations. This requires a
sufficient amount of cells that are able to expand and respond to tumor or viral antigens.
The cytokines interleukin (IL)-2 and IL-7 drive T cell differentiation, proliferation, and
survival and are commonly used to expand T cells ex vivo. Here, we have used microchip-
based live-cell imaging to follow the migration of individual T cells, their interactions
with allogeneic monocytes, cell division, and apoptosis for extended periods of time;
something that cannot be achieved by commonly used methods. Our data indicate that
cells grown in IL-7+ IL-2 had similar migration and contact dynamics as cells grown in
IL-2 alone. However, the addition of IL-7 decreased cell death creating a more viable cell
population, which should be beneficial when preparing cells for immunotherapy.
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Introduction
T cells have been used in several adoptive cellular immunotherapies, which have shown promise as
treatment for various cancers and infectious agents (1–4). The quality, the degree of activation, and
the T cell profile are of central importance for clinical efficacy. Numerous in vitro T cell activation
and expansion techniques have been described in previous studies, including use of anti-CD3- and
anti-CD28-coated super paramagnetic beads and interleukin (IL)-2, in order to achieve high enough
numbers of cells to be used clinically (5, 6). In addition, cytokines represent a polarizing signal
that drives the development of recently activated, naïve CD4+, and CD8+ T cells toward various
effector subsets (7–11). Accordingly, T cell expansion can be further propagated and controlled by
the addition of various cytokines. The T cell growth factor IL-2 has well-documented effects on T
cells from both in vitro models (12) and clinical trials (13–17). However, IL-2 administration has
been shown to alter the homeostasis and increase the amount of CD4+CD25hiFoxp3+ regulatory
T cells (T regs) in cancer patients dampening the desired response (18). In contrast, patients with
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metastatic cancers receiving IL-7 therapy showed a decrease of
regulatory T cells and increases in CD4+ and CD8+ T cells (19).
IL-7 has also been shown to enhance T cell proliferation, reduce
activation-induced apoptosis and increase TCR diversity (20, 21).
A new fully glycosylated recombinant human (rh) IL-7
(Cyt107) was recently used in a clinical phase 1 study to enhance
T-cell recovery after allogeneic stem cell transplantation (22). As
previously reported, the treatment was shown to be well tolerated
and safe (19, 22–27). Moreover, it has been shown that the combi-
nation of IL-2 and IL-7 can be used to modulate the proliferation
and Fas-mediated cell death of distinct T cell subsets (28). Trig-
gered by these observations, we set out to compare phenotypic
and functional properties of T cells expanded in presence of anti-
CD3- and anti-CD28-coated beads and IL-2 with or without the
addition of rhIL-7. Hitherto, most of the in vitro characterization
of expanded T cells is based on data from phenotype classification
and cytokine profiles of T cells. Here, we have used a recently
developed microchip-based approach (29–31) where we were
able to follow the motility and cell–cell interaction patterns of
individual T cells for hours in co-culture with allogeneic target
cells.
Materials and Methods
Cell Culture
Peripheral blood mononuclear cells (PBMC) were isolated from
whole blood from 12 anonymous healthy donors using density
gradient centrifugation (Lymphoprep, Fresenius Kabi Norge AS).
According to local regulations, no ethical permit was required for
anonymous blood donors. T cells were isolated from PBMC by
use of paramagnetic beads coated with anti-CD3 and anti-CD28
antibodies (Dynabeads, Life Technologies, Grand Island, NY,
USA) according to the manufacturer’s protocol. The isolated cells
were expanded for 7 days together with the anti-CD3 and anti-
CD28 beads in RPMI-1640 (Gibco, Life Technologies) contain-
ing 5% Human AB serum (Department of transfusion Medicine
at Karolinska University Hospital, Huddinge), 100U/mL Peni-
cillin G, 100 µg/mL Streptomycin (Gibco, Life Technologies), and
2mM -glutamine (Sigma Aldrich Inc., St Louis, MO, USA).
The cells were divided into two flasks, either with 100 IU/mL IL-
2 (PeproTech, Rocky Hill, NJ, USA) or with a combination of
100 IU/mL IL-2 and 0.5 ng/mL rhIL-7 (Cyt107, Cytheris). Cells
were cultured at 37°C, 5% CO2 and kept at a concentration of
less than 3 105 cells/mL. After 7 days of expansion, T cells were
harvested and beads were removed from the cells by magnetic
separation. Allogeneicmonocytes were isolated fromPBMCat the
day of the experiment by allowing them to adhere to the bottom
of a six-well plate. The non-adherent cells were removed and the
adherent cells were mechanically detached from the wells before
labeling and seeding in microwells. Allogeneic monocytes were
chosen in order to stimulate interaction between T cells and target
cells.
Cell Labeling
1 106 cells were washed three times in RPMI-1640 and then
stained with 0.5 µM Calcein Green AM (target cells) or 0.64 µM
Calcein Red–Orange AM (T cells) (both dyes from Invitro-
gen, Carlsbad, CA, USA). Staining solutions were prepared with
RPMI-1640 as solvent and added directly to the cell pellets, which
were re-suspended and incubated for 10min at 37°C. After stain-
ing, cells were washed three times in RPMI-1640 and used for
experiments.
Microchip
The microchip was prepared as described earlier (29). Briefly,
the microchip was sterilized in ethanol and all traces of ethanol
were removed by washing the chip in PBS after which the holder
and chip were assembled. To enable imaging of two conditions
simultaneously, the microchip was divided into two basins, one
with IL-2 medium and the other with IL-2+ IL-7 medium by use
of a polydimethylsiloxane (PDMS) gasket. Fluorescently labeled
allogeneic target cells were added to each basin to a desired density
(60 cells/well) and excess cells were removed by changing the
medium in the chip. The target cells were then allowed to adhere
for 1 h after which Calcein Red–Orange AM-labeled T cells from
either the IL-2 only or IL-2+ IL-7 cultures were added to the chip
(50 T cells/well) and were allowed to settle by sedimentation.
Microscopy
Fluorescence and transmitted light images were obtained with
an Olympus IX81-inverted confocal fluorescence microscope
equipped with an environmental chamber keeping the cells at
37°C, 5% CO2. A motorized stage enabled automatic collection of
images from selected parts of themicrochip. For each experiment,
four wells (two per condition) were imaged every 2min for a
period of 7 h with a 20 objective. The presented data are from
three independent experiments with at total of 219 (IL-2) and 175
(IL-2+ IL-7) T cells, respectively.
Image Analysis
Images were analyzed with ImageJ software (US National Insti-
tutes of Health, Bethesda, MD, USA). Each T cell was manually
tracked and interactions with target cells were scored. Interactions
with target cells lasting at least two time points (4min) were
defined as a T cell contact with a target cell. Cell death was defined
as visual signs of death in the transmitted light image, usually seen
as blebbing or swelling of the cell membrane and/or leakage of the
fluorescent dye. Cells that could not be followed for at least 60min
were excluded from the analysis.
Immunophenotyping
After 7 days of expansion, T cells were harvested and immunophe-
notyping was performed. T cells were incubated with the follow-
ing monoclonal antibodies: fluorescein isothiocyanate (FITC)-,
phycoerythrin (PE)-, PE-cyanine 7 (PE-Cy7)-, and V450-labeled
anti-CD3; allophycocyanin (APC)-, and Alexa Fluor 700-labeled
anti-CD4; Peridinin-chloropyll-protein complex (PerCP)-labeled
anti-7-Aminoactinomycin D (7-AAD); FITC-labeled anti-CD28;
FITC-labeled anti-CD69; FITC-labeled anti-CD94; FITC-labeled
anti-CD56; FITC-labeled anti-TCRαβ; FITC-labeled anti-CD95;
APC-labeled anti-CD45RO; PE-Cy7-labeled anti-CCR7; FITC-
labeled anti-CD25; APC-labeled Annexin V (all from BD Bio-
science, Franklin Lakes, NJ, USA); FITC-labeled anti-TCRγδ
(Becman Coulter, Fullerton, CA, USA); APC-Alexa Fluor 700-
labeled anti-CD127 (Beckman Coulter, Fullerton, CA, USA);
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Pacific Orange-labeled anti-CD8 (Invitrogen); PE-labeled anti-
CD39 (BD Bioscience, Franklin lakes, NJ, USA) for 15min and
washed before flow cytometry (FACS Aria flow cytometer, BD
Biosciences) and analysis (FlowJo software, Tree Star, Inc., Ash-
land, OR, USA). T cell death was assessed by flow cytometry
staining for 7-AAD andAnnexin V after 7 days culture with beads
and cytokines followed by a brief (6 h) period of stimulation with
peptide mix spanning the cytomegalovirus (CMV) protein pp65.
Statistical Analysis
Statistical analysis was performed with Prism (GraphPad, San
Diego, CA, USA) or Matlab (MathWorks, MA, USA) using the
Mann–Whitney U test to evaluate migration and bulk expansion
data, theWilcoxonmatched-pairs signed rank test to compare fold
expansion data and Chi-square test to evaluate cell–cell contacts,
cell division, and cell death. In the images, stars have been used to
denote significance levels according to; * (p< 0.05), ** (p< 0.01)
and “n.s.” refers to no statistical significance. Box-and-whisker
plots indicate second and third quartiles separated by the median
(inside the box) and whiskers show minimum and maximum
values.
Results
Expansion of T-Cells with IL-2 or IL-2+ IL-7
We set out to test if the addition of a fully glycosylated form of
rhIL-7 (Cyt107) could improve the yield and quality of T cells
compared to an expansion protocol with only IL-2. This form of
IL-7 was recently used in a clinical setting to successfully enhance
T cell recovery after allogeneic stem cell transplantation (22). T
cells were positively selected from PBMCwith anti-CD3 and anti-
CD28 paramagnetic beads and cultured in medium containing
IL-2 alone or a combination of IL-2 and IL-7. Cells were cul-
tured for 7 days and kept at a concentration of no more than
3 105 cells/mL. The yield varied significantly between individual
expansions (n= 12) for both culturing conditions; the combina-
tion of IL-2 and IL-7 showed the fold-increase range 12–193 with
median 51 while IL-2 alone gave a range of 10–183 and median
50. Addition of IL-7 led to increased cell numbers in 7 out of
12 expansions, while 2 expansions showed similar numbers for
both conditions and three expansions gave a higher fold expansion
for IL-2 alone, shown as the ratio of fold increase in IL-2+ IL-7
over IL-2 at day 7 for each experiment (Figure 1A); however, no
statistically significant difference was found (p= 0.52, Wilcoxon
matched-pairs signed rank test). Kinetic analysis of T cell prolifer-
ation showed that cell numbers increased exponentially until the
end of culture at 7 days for both conditions (Figure 1B; Figure S1
in Supplementary Material). Thus, both culture conditions stim-
ulated substantial T cell proliferation displaying large variations
between individual blood donors and addition of IL-7 had no
statistically significant effect on the total T cell yield.
IL-7 Did Not Affect Expression of Phenotypic
Markers of Peripheral Blood-Derived T Cells
When T cells are activated and expanded in vitro, their phenotype
and function change. In order to test if addition of IL-7 had an
FIGURE 1 | Effect of IL-7 on T cell expansion and phenotype. T cells
were positively selected and cultured for 7 days with anti-CD3- and
anti-CD28-coated beads and IL-2+ IL-7 or IL-2 alone, after which the cells
were counted and phenotyped by flow cytometry and the expressions of
CD4, CD8, CCR7, CD45RO, γδ-TCR, CD25, and CD39 were compared
between the two culture conditions. (A) Relative T cell expansion displayed as
ratio of fold increase in IL-2+ IL-7 over IL-2. (B) Kinetics of fold expansion for
one representative donor. This donor gave median fold expansion after 7 days
for both culture conditions. (C) CD4/CD8 ratio. (D) Distribution of memory
subsets. T cell maturation profile from least mature to most mature was
defined as: CCR7+CD45RO  (naïve, red); CCR7+CD45RO+
(early-differentiated, blue); CCR7 CD45RO+ (intermediate-differentiated,
yellow); CCR7 CD45RO  (late-differentiated, orange). (E) Percentage of
CD3+CD4 CD8  T cells expressing γδ-TCR. (F) Percentage of regulatory T
cells, defined as CD3+CD4+CD127 CD25+CD39+. Flow cytometry data
are based on data from 9 individual donors, and cell expansion data is based
on 12 individual experiments. Lines connect cultures from the same donor,
horizontal lines in (A) depict the median and IQR. Mann–Whitney tests were
performed to evaluate significance between the groups.
affect over IL-2 on the T cell phenotype, anti-CD3- and anti-
CD28-activated peripheral blood-derived T cells cultured in IL-
2+ IL-7 or IL-2 alone for 7 days were analyzed bymulti-color flow
cytometry (see Figure S2 in Supplementary Material for gating
strategy). First, the CD4/CD8 ratios were compared, displaying
significant variation between individual donors but no statisti-
cally significant difference correlated to the addition of IL-7 was
detected (medians were 3.1 and 3.5 for IL-2 and IL-2+ IL-7,
respectively) (Figure 1C).
Next, we tested the effect of IL-7 on differentiation. Stages
of differentiation were defined based on expression of CCR7
and CD45RO. Naïve T cells were defined as CCR7+CD45RO ;
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early-differentiated T cells as CCR7+CD45RO+; intermediate-
differentiated T cells as CCR7 CD45RO+; and late-differentiated
as CCR7 CD45RO  (32, 33). No significant differences were
seen for memory T cell subsets in the CD3+ T cell compartment
when T cells were expanded in the presence or absence of IL-
7 (Figure 1D). In both conditions, intermediate-differentiated T
cells were the most frequently observed population followed by
early-differentiated T cells, late-differentiated T cells, and naïve T
cells.
Furthermore, the percentage of γδ-T cells was compared
between cultures with or without IL-7. No difference in
CD3+CD4 CD8  T cells expressing γδ-TCR was observed
(Figure 1E). It has been described that treatment with IL-2 may
increase the amount of regulatory T cells in cancer patients (18),
while IL-7 may have opposite effects (19). Therefore, the propor-
tions of T regs (defined as CD3+CD4+CD127 CD25+CD39+)
were compared between the two culture conditions but no differ-
ence was detected (Figure 1F). Thus, these results show that for T
cells expanded in vitro from peripheral blood the addition of IL-7
had little effect on CD4/CD8 ratio, memory status and frequency
of regulatory T cells.
Addition of IL-7 Does Not Influence T Cell
Migration and Interaction with Target Cells
To investigate the impact that the expansion protocols had on
T cell behavior, a microchip-based live-cell imaging assay was
used (Figure 2). With this approach, time-lapse imaging enabled
a detailed comparison of migration and interaction properties of
individual T cells over time between cultures expanded with or
without IL-7. T cells collected after both culture conditions were
fluorescently stained and seeded to separate microwells loaded
with allogeneicmonocytes. Two to fourmicrowells for each exper-
imental condition were selected and automatically imaged peri-
odically with a confocal microscope equipped with a motorized
stage creating up to four individual time-lapse movies from each
experiment. Individual T cells were tracked and their interactions
with allogeneic target cells recorded.
The median migration speeds for T cells were 2.8 µm/min for
both culture conditions (Figure 3A). The percentage of time a T
cell spent in contact with target cells during the entire assay of
7 h was also assessed (Figure 3B). Among the T cells that made
contact with target cells, the vast majority spent a low fraction of
time (<20%) in contact while others remained in contact during
the whole assay (Figure 3B). Evaluation of the duration of all
individual contacts between T cells and target cells during the
assay showed that most contacts were brief, with a median of
8min for both culture conditions (Figure 3C). However, also
significantly longer contacts were observed, some of them lasting
up to 7 h. For cells cultured in IL-2 only, 42.5% made contact
with a target cell during the assay whereas 35.4% of the cells cul-
tured in a combination of IL-2+ IL-7 made contacts (Figure 3D).
Individual T cells were observed to make contact with up to
seven individual target cells during the 7-h assay. No statistically
significant difference was observed in the number of contacts
made by T cell from the two populations. The data in Figure 3 are
pooled from three independent experiments, which are presented
separately in Figure S3 in Supplementary Material.
FIGURE 2 | Long-term live-cell imaging in microwells for
characterization of migration and contact dynamics. (A) Schematic
picture of the device consisting of a metal holder (1), multi-well silicon-glass
microchip (2), PDMS gasket (3), and lid (4). The lid was held tightly against the
metal holder by magnets. The PDMS gasket was cut to create two separate
basins (one per condition), each containing approximately 30 microwells.
(B) Scanning electron microscopy image showing a subsection of the
microchip. The dimension of the microwell bottom was 450450 µm2 and
the well depth was 300 µm. (C) Fluorescence image of a microwell containing
T cells (red) and target cells (green). (D) Trajectories from T cells (n=23)
followed in a representative time-lapse sequence.
When T cells made contact with target cells, the most common
observation made was that the T cells scanned the surface of
the target cell, detached, and continued migrating (Figure 4A).
Although the vast majority of T cell–target cell interactions did
not result in T cell-mediated target cell killing, a few killing
events could be observed in the time-lapse movies (Figure 4B). In
these events, target cells engaged in conjugates with T cells were
observed to change their morphology manifested as membrane
blebbing, swelling, and bursting correlatedwith decreased fluores-
cence intensity due to leakage of calcein. However, too few events
were observed in order to assess any difference between culture
conditions.
Addition of IL-7 Decreases Cell Death But Shows
No Effect on the Rate of Mitosis
Stimulation with anti-CD3- and anti-CD28-coated paramagnetic
beads efficiently induced T cell proliferation in both culture con-
ditions tested. However, for T cells used in immunotherapy, it
is of central importance that expanded cells are of high quality
and retain a proliferative capacity after injection. Therefore, the
frequency of cell division (Figures 5A,B) in relation to cell death
(Figures 5C,D) was assessed from the time-lapse movies. While
no difference in cell divisionwas observed between the two culture
conditions, it was found that the rate of cell death was higher
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FIGURE 3 | Addition of IL-7 does not influence T cell migration and
target cell interaction dynamics. (A) Box plot of T cell migration speed for
the two conditions. The mean speed of T cells cultured in IL-2 (red, n= 219,
median 2.8 µm/min), and T cells cultured in IL-2+ IL-7 (blue, n= 175, median
2.8 µm/min). (B) The fraction of time (%) spent in contact with target cells
shown for cells cultured in IL-2 (red, n= 219) or IL-2+ IL-7 (blue, n= 175)
during the time interval they were followed. (C) Boxplot of the duration of all
individual contacts scored between T and target cell during the 7-h assay for
the two conditions (n= 152 for IL-2 and n= 125 for IL-2+ IL-7). Median
times per contact were 8min for both conditions. (D) Histogram showing the
number of contacts made with target cells by individual T cells (%) during the
7-h assay for cells cultured in IL-2 (red bars, n= 219 cells) or in IL-2+ IL-7
(blue bars, n= 175 cells). Mann–Whitney tests were performed to compare
mean speed, fraction of time in contact, time spent in each individual contact,
and number of contacts made by each T cell between the two culture
conditions.
for T cells expanded in IL-2 alone (p< 0.005, Chi-square test)
(Figure 5). The data in Figure 5 are pooled from three inde-
pendent experiments, which are presented separately in Figure
S3J,K in Supplementary Material. However, when cell death was
measured by flow cytometry, staining for the markers 7-AAD and
Annexin V after 7 days of culture followed by a brief period of
peptide stimulation, no differences in the rate of cell death were
observed between the two culture conditions, and the percentages
of dead cells were low (median 4.9% for IL-2 vs. 4.1% for IL-2+ IL-
7, Figure S2F in Supplementary Material). Thus, taken together
our data indicate that any beneficial effect for T cell yield given
by addition of IL-7 at these cytokine concentrations is not due
to increased proliferation but rather increased tolerance to stress
leading to better survival.
Discussion
For patients where T cell immunotherapy may be considered, the
quality and number of lymphocytes to be infused are of central
importance for the clinical outcome. Stable and reproducible T cell
culture protocols in combination with efficient evaluation meth-
ods are needed. Progress has been made in designing strategies
to analyze both the frequency of specific T cells and their ability
FIGURE 4 | T cell–target cell interactions were brief or more stable,
sometimes leading to target cell death. (A) Time-lapse sequence
showing a T cell forming a brief contact with a target cell. The panels show
transmitted light (top), fluorescence showing T cells in red and target cells in
green (middle) and fluorescence overlaid with the T cell trajectory (white line,
bottom). A T cell (marked by arrowheads) migrated toward a target cell (frame
1), formed a contact with the target cell (frame 2), continued migrating while
attached to the target cells, scanning the target cell surface (frames 3 and 4),
and finally detached without forming a stable conjugate or killing the target
cell (frame 5). (B) Time-lapse sequence showing T cell-mediated target cell
death. Panels as in (A). A T cell (marked by arrowheads) migrated with an
elongated shape (frame 1), made a contact with a target cell within a cluster
of three cells (frame 2), rounded up, and formed a conjugate (frame 3), which
was followed by target cell death seen as a decreased green fluorescence
intensity and a cloud of cellular debris in the transmitted light channel (frames
4 and 5). Indicated times are hours:minutes and scale bar represent 20 µm.
Images have been resampled and brightness and contrast altered to improve
visibility.
to produce cytokines at a single-cell level. New multiparametric
flow cytometry assays combining phenotypic and functional char-
acterization of T cell populations are now used frequently due to
their ability to measure multiple cytokines and provide detailed
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FIGURE 5 | Addition of IL-7 had no effect on rate of T cell mitosis but
decreased cell death. (A) Percentage of T cells undergoing mitosis during
the 7-h assay for the two conditions. (B) Time-lapse imaging data of cell
division shown in transmission (top) and fluorescence (bottom). A T cell (red
fluorescence) migrated with a typically elongated, migratory shape (frame 1)
and stopped, enlarged, and rounded up (frame 2), this interphase was
followed by mitosis where the cells split into two daughter cells (frames 3 and
4) and finally cytokinesis (frame 5), where the new cells were divided. Indicated
times are hours:minutes and the scale bar represents 10 µm. (C) Percentage
of T cells dying during the 7-h assay for the two conditions (p<0.005).
(D) Time-lapse imaging data of T cell death shown in transmission (top),
fluorescence (bottom). A migrating T cell (red fluorescence) stopped and
rounded up (frame 1), followed by cell death seen as membrane blebbing in
the transmitted light image (top) and decreased red fluorescence intensity
(bottom) (frames 2–5). Indicated times are hours:minutes and scale bar
represents 10 µm. Chi-squared test was used to compare the rate of cell
death and mitosis between the two culture conditions. The data in (A,C) are
based on three individual experiments (IL-2 n= 219, IL-2+ IL-7 n= 175).
Images have been resampled and brightness and contrast altered to improve
visibility.
information about phenotypically different subpopulations. How-
ever, these methods do not reveal dynamical properties such as
migration and formation of immune synapses, properties that are
central for a functioning T cell response.
Here, we use a recently developed microchip-based, live-cell
imaging approach, with single-cell resolution (29–31). This assay
enables detailed characterization of individual T cells’ migration
behavior and contact history over time as well as information
about cell division and apoptosis. With this method, it is also
possible to detect rare events occurring in small subpopulations of
tumor-reactive T cell clones. Together with other recently devel-
oped microchip methods, e.g., microengraving (34, 35), this tool
could be valuable for how to select and expand cells for therapy.
A central issue for adoptive T cell-based immunotherapies is
how to generate enough functional cells in adequate time. In the
present study, efficient T cell expansion was obtained within a
week by co-culturing peripheral blood-derived T cells with artifi-
cial APCs, i.e., anti-CD3- and anti-CD28-coated beads. Cytokines
were added to induce further activation and modulation of the
expanding T cell population. IL-2 is the most frequently used
cytokine for this purpose as it is a potent T cell mitogenic cytokine
and essential for the growth, proliferation, and differentiation of
T cells. Generally, this type of T cell expansion protocol generates
large numbers of polyclonal T cells within a relatively short time.
However, IL-2 has been shown to be involved in the priming
of mature T cells for activation-induced cell death by enhanc-
ing expression of pro-apoptotic molecules such as FasL, and to
suppress apoptosis inhibitors of Fas signaling (36). A possible
drawback with this type of protocol is therefore the risk for
massive apoptosis after injection due to sudden withdrawal of
cytokines (37).
In an attempt to generate an expanded T cell population with
better capacity to survive, IL-7 was added to the T cell cultures.
IL-7 has also been shown to enhance T cell proliferation, but in
contrast to IL-2 it has been reported to also reduce activation-
induced apoptosis (38). In the present study, we used a fully
glycosylated form of IL-7 that has been shown in a clinical phase
1 study to successfully enhance T cell recovery after allogeneic
HSCT (22). Our proliferation studies of bulk cultures indicated
little or no beneficial effects from the addition of IL-7, and no
phenotypic differences were detected between cells cultured with
or without IL-7. This is not in line with our previous experiments
from cord blood-derived T cells where an increased expansion
was observed after the addition of IL-7 (39). In the earlier study,
we also observed that the CD4/CD8 ratio was higher in cultures
containing IL-7 and IL-2 compared to IL-2 alone (median 3.0 vs.
2.4). In the present study, we see a slightly higher CD4/CD8 ratio
for T cells cultured in a combination of IL-2+ IL-7 compared
to IL-2 only (median 3.5 vs. 3.1); however, this did not reach
statistical significance. Berglund et al. used IL-7 produced in
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E. coli, with a glycosylation pattern differing from that found in
eukaryotic cells, something that could possibly account for the
differences observed. In addition, that study used CB-derived T
cells, which are known to have amore naïve phenotype thanT cells
isolated from PBMC that were used in the present study, changing
the response pattern to cytokine exposure.
The microchip-based time-lapse imaging assay was used to
evaluate the behavior and survival capacity of the T cells at a time
point (7 days) when cells expanded for T cell-based immunother-
apy are normally injected into the patient. Most T cells making
contact with target cells were observed to scan the surface of
the target cell rather than forming stable immune synapses. This
behavior is consistent with only a small fraction of the T cells
being allospecific. T cell migration and contact dynamics were
found to be similar under the two culturing conditions. However,
we observed a significant decrease in T cell death in the imaging
experiments with the addition of IL-7. This decrease was not
reflected in the flow cytometry analysis using the markers 7-
AAD and Annexin V for measuring cell death. A reason why we
observe more cell death in the imaging experiments could be that
some of the dying cells rapidly disintegrate, and while such death
is detected by imaging it is not by flow cytometry where such
cells are instead washed away in the cleaning steps. However, it
is plausible that there were negative effects from the microchip
assay with fluorescence labeling and repeated imaging, although
similar protocols have proved functional and non-harmful for IL-
2-activated natural killer cells (29, 30). It is possible that the T cells
generated with these protocols are over-stimulated and easily die
when separated from the anti-CD3 and anti-CD28 beads and/or
handled in the lab. Either way, the cells could face similar stress
during preparation and infusion in a clinical setting resulting in a
large fraction of the cells dying shortly after infusion. Our imaging
data indicate that the addition of IL-7 makes the T cells more
resistant to stress.
In summary, there is a need for methods that can probe the
condition of cells expanded for immunotherapy. The microchip-
based assay presented here allows for assessment of cellular behav-
ior that could be of clinical interest, including migration proper-
ties, interaction and killing of target cells, mitosis, or apoptosis.
Since detection is at the single-cell level, it allows characterization
also of rare clones within populations, clones that could have
beneficial or detrimental clinical impact. Relatively little mate-
rial is required to run the assay making it possible to study the
behavior of cells from small clinical samples. Increased knowl-
edge of the behavior and survival capacity of in vitro cultured
lymphocytes aimed for treatment of various immunological issues
opens for new immunotherapeutic perspectives with implications
in areas such as transplantation medicine, autoimmune diseases,
and HIV/AIDS research.
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